Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness

Llorca, Pierre Michel; Abbar, Mocrane; Courtet, Philippe; Guillaume, Sebastien; Lancrenon, Sylvie; Samalin, Ludovic

doi:10.1186/1471-244x-13-340

Cited by 188Schizophrenia research and treatmentPsychiatric care and mental health servicesTreatment of Major Depression

Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness

Open access

Llorca, Pierre Michel, Abbar, Mocrane, Courtet, Philippe, Guillaume, Sebastien, Lancrenon, Sylvie, Samalin, Ludovic·2013·BMC Psychiatry

DOI 10.1186/1471-244x-13-340PMC PMC3898013

Open this paper in CoChat — free account Open PDF

Abstract

Background: Long-acting injectable (LAI) formulations are not widely used in routine practice even though they offer advantages in terms of relapse prevention. As part of a process to improve the quality of care, the French Association for Biological Psychiatry and Neuropsychopharmacology (AFPBN) elaborated guidelines for the use and management of antipsychotic depots in clinical practice. Methods: Based on a literature review, a written survey was prepared that asked about 539 options in 32 specific clinical situations concerning 3 fields: target-population, prescription and use, and specific populations. We contacted 53 national experts, 42 of whom (79%) completed the survey. The options were scored using a 9-point scale derived from the Rand Corporation and the University of California in the USA. According to the answers, a categorical rank (first-line/preferred choice, second-line/alternate choice, third-line/usually inappropriate) was assigned to each option. The first-line option was defined as a strategy rated as 7–9 (extremely appropriate) by at least 50% of the experts. The following results summarize the key recommendations from the guidelines after data analysis and interpretation of the results of the survey by the scientific committee. Results: LAI antipsychotics are indicated in patients with schizophrenia, schizoaffective disorder, delusional disorder and bipolar disorder. LAI second-generation antipsychotics are recommended as maintenance treatment after the first episode of schizophrenia. LAI first-generation antipsychotics are not recommended in the early course of schizophrenia and are not usually appropriate in bipolar disorder. LAI antipsychotics have long been viewed as a treatment that should only be used for a small subgroup of patients with non-compliance, frequent relapses or who pose a risk to others. The panel considers that LAI antipsychotics should be considered and systematically proposed to any patients for whom maintenance antipsychotic treatment is indicated. Recommendations for medication management when switching oral antipsychotics to LAI antipsychotics are proposed. Recommendations are also given for the use of LAI in specific populations. Conclusion: In an evidence-based clinical approach, psychiatrists, through shared decision-making, should be systematically offering to most patients that require long-term antipsychotic treatment an LAI antipsychotic as a first-line treatment.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1186/1471-244x-13-340

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The current and future increasing availability of LAIs will enrich the choice for clinicians who intend to use a long-acting formulation.
“The current and future increasing availability of LAIs will enrich the choice for the clinicians who intend to use a long-acting formulation [67].”
From The role of shared decision-making in improving adherence to pharmacological treatments in patients with schizophrenia: A clinical review (2020) · cites this paper as [67]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930 · cited 2× · see citing works
“Some individual oral SGA (amisulpride, clozapine, olanzapine, risperidone) were better in overall efficacy in patients with schizophrenia than oral FGA [17].”
Background
Prevalence of and Risk Factors for Medication Nonadherence in Patients With Schizophrenia: A Comprehensive Review of Recent Literature
Lacro, J. P., Dunn, L. B., Dolder, C. R., Leckband, S. G., & Jeste, D. V. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1007 · Cited by 1,383 · cited 1× · see citing works
“For example, the majority of patients with schizophrenia (84%) discontinue their index antipsychotic during the follow-up period [2] and in the long-term perspective, 40 to 50% seem to be noncompliant [3], with no real difference in terms of adherence between first-generation antipsychotics (FGA) and second-generation…”
Background
Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology
Goodwin, G., Haddad, P. M., Ferrier, I. N., Aronson, J., Barnes, T., Cipriani, A., Coghill, D., Fazel, S., Geddes, J. R., Grunze, H., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116636545 · Cited by 1,314 · see citing works
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Beaulieu, S., Alda, M., O’Donovan, C., MacQUEEN, G. M., McIntyre, R. S., Sharma, V., et al. (2012) · Bipolar Disorders · doi:10.1111/bdi.12025 · Cited by 1,209 · see citing works
The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements
Buchanan, R. W., Kreyenbuhl, J. A., Kelly, D. L., Noel, J. M., Boggs, D. L., Fischer, B. A., Himelhoch, S. S., Fang, B., Peterson, E. L., Aquino, P. R., et al. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp116 · Cited by 901 · cited 2× · see citing works
“With regards to non-adherence, most of the guidelines and algorithms (except PORT 2009) state that depot antipsychotics are an effective approach [8-10], with some guidelines actually recommending that switching the antipsychotic formulation from oral to depot should be considered in maintenance treatment [11].”
Background
Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis
Rummel‐Kluge, C., Komossa, K., Schwarz, S., Hunger, H., Schmid, F., Lobos, C. A., Kissling, W., Davis, J. M., & Leucht, S. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.07.012 · Cited by 679 · cited 1× · see citing works
“Oral SGA induced fewer extrapyramidal side effects than oral FGA but some SGA induced more weight gain or metabolic side effects than oral FGA [41,42].”
Background
The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness.
Velligan, D. I., Weiden, P. J., Sajatovic, M., Scott, J. L., Carpenter, D., Ross, R., & Docherty, J. P. (2009) · PubMed · Cited by 625 · see citing works
Partial Compliance and Risk of Rehospitalization Among California Medicaid Patients With Schizophrenia
Weiden, P. J., Kozma, C., Grogg, A., & Locklear, J. (2004) · Psychiatric Services · doi:10.1176/appi.ps.55.8.886 · Cited by 621 · cited 1× · see citing works
“81 in patients with schizophrenia [37].”
Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology
Barnes, T. R. E., Drake, R., Paton, C., Cooper, S. J., Deakin, J. F. W., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I. R., et al. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 607 · see citing works
A Meta-Analysis of Head-to-Head Comparisons of Second-Generation Antipsychotics in the Treatment of Schizophrenia
Leucht, S., Komossa, K., Rummel‐Kluge, C., Corves, C., Hunger, H., Schmid, F., Lobos, C. A., Schwarz, S., & Davis, J. M. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08030368 · Cited by 489 · cited 1× · see citing works
“and tolerability (especially for SGA) [17,18].”
Evidence-based guidelines for treating bipolar disorder: revised second edition—recommendations from the British Association for Psychopharmacology
Goodwin, G. M. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109102919 · Cited by 443 · cited 1× · see citing works
“Indeed, the current EBG for biological treatment of schizophrenia and bipolar disorder [8-10,45-53] propose few recommendations concerning LAI antipsychotics.”
Background
The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2012 on the long-term treatment of bipolar disorder
Grunze, H., Vieta, E., Goodwin, G. M., Bowden, C. L., Licht, R. W., Möller, H., Kasper, S. F., & on behalf of the WFSBP Task Force on Treatment Guidelines for Bipolar Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.770551 · Cited by 421 · cited 1× · see citing works
“Indeed, the current EBG for biological treatment of schizophrenia and bipolar disorder [8-10,45-53] propose few recommendations concerning LAI antipsychotics.”
Background
Oral versus depot antipsychotic drugs for schizophrenia—A critical systematic review and meta-analysis of randomised long-term trials
Leucht, C., Heres, S., Kane, J. M., Kissling, W., Davis, J. M., & Leucht, S. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2010.11.020 · Cited by 419 · cited 2× · see citing works
“If their use in schizophrenia is common and supported by evidence [5-7,28], their use in bipolar disorder is less obvious.”
Background
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J. A., Glenthoj, B. Y., Gattaz, W. F., Thibaut, F., Möller, H., & WFSBP Task force on Treatment Guidelines for Schizophrenia (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.739708 · Cited by 418 · cited 2× · see citing works
“Perhaps the follow-up period, lasting a year or less, may have been too short to reveal the longer-term benefits of depot treatment versus oral form [9,46].”
Background
The Expert Consensus Guideline Series
Karceski, S. C., Morrell, M. J., & Carpenter, D. P. (2001) · Epilepsy & Behavior · doi:10.1006/ebeh.2001.0283 · Cited by 397 · see citing works
Long-Acting Injectable vs Oral Antipsychotics for Relapse Prevention in Schizophrenia: A Meta-Analysis of Randomized Trials
Kishimoto, T., Robenzadeh, A., Leucht, C., Leucht, S., Watanabe, K., Mimura, M., Borenstein, M., Kane, J. M., & Correll, C. U. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs150 · Cited by 395 · cited 2× · see citing works
“If their use in schizophrenia is common and supported by evidence [5-7,28], their use in bipolar disorder is less obvious.”
Background
Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology
Barnes, T. R. E. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110391123 · Cited by 357 · cited 1× · see citing works
“Indeed, the current EBG for biological treatment of schizophrenia and bipolar disorder [8-10,45-53] propose few recommendations concerning LAI antipsychotics.”
Background
Guidelines for depot antipsychotic treatment in schizophrenia
Kane, J. M., Aguglia, E., Altamura, A. C., Gutiérrez, J. L., Brunello, N., Fleischhacker, W. W., Gaebel, W., Gerlach, J., Guelfi, J.-D., Kissling, W., et al. (1998) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(97)00045-x · Cited by 331 · see citing works
Treatment of Schizophrenia
Kane, J. M. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.1.133 · Cited by 325 · see citing works
The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary
Kane (2003) · The Journal of Clinical Psychiatry · Cited by 324 · see citing works
Introduction: Methods, Commentary, and Summary
Alexopoulos, G. S., Streim, J. E., Carpenter, D. P., & Docherty, J. P. (2004) · The Journal of Clinical Psychiatry · Cited by 316 · see citing works
The Texas Medication Algorithm Project Antipsychotic Algorithm for Schizophrenia
Moore, T. A., & Buchanan, R. W. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n1115 · Cited by 288 · see citing works
Systematic meta-review of depot antipsychotic drugs for people with schizophrenia
Adams, C. E., Fenton, M., Quraishi, S. N., & David, A. S. (2001) · The British Journal of Psychiatry · doi:10.1192/bjp.179.4.290 · Cited by 286 · cited 3× · see citing works
“If their use in schizophrenia is common and supported by evidence [5-7,28], their use in bipolar disorder is less obvious.”
BackgroundResult
Second-Generation Antipsychotic Drugs and Extrapyramidal Side Effects: A Systematic Review and Meta-analysis of Head-to-Head Comparisons
Rummel‐Kluge, C., Komossa, K., Schwarz, S., Hunger, H., Schmid, F., Kissling, W., Davis, J. M., & Leucht, S. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq042 · Cited by 272 · cited 1× · see citing works
“Oral SGA induced fewer extrapyramidal side effects than oral FGA but some SGA induced more weight gain or metabolic side effects than oral FGA [41,42].”
Background
Introduction: Methods, Commentary, and Summary
Allen, M. H., Currier, G. W., Carpenter, D. P., ROSS, R. W., & Docherty, J. P. (2005) · Journal of Psychiatric Practice · doi:10.1097/00131746-200511001-00002 · Cited by 265 · cited 1× · see citing works
“This method is very close to the Expert Consensus Guidelines methodology and has been applied to a variety of psychiatric disorders [4,21-27].”
Method
The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.
Kane, J. M., Leucht, S., Carpenter, D. P., & Docherty, J. P. (2003) · PubMed · Cited by 234 · see citing works
CLINICAL PRACTICE GUIDELINES Treatment of Schizophrenia
Paris, J., Bland, R. C., Goldbloom, D. S., Grof, P., LESAGE, A. D., Streiner, D. L., Addington, D. E., Arboleda‐Flórez, J., Benkelfat, C., Bond, M., et al. (2005) · Cited by 184 · see citing works
Strategies for Addressing Adherence Problems in Patients with Serious and Persistent Mental Illness: Recommendations From the Expert Consensus Guidelines
Velligan, D. I., Weiden, P. J., Sajatovic, M., Scott, J. L., Carpenter, D. P., ROSS, R. W., & Docherty, J. P. (2010) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000388626.98662.a0 · Cited by 180 · cited 1× · see citing works
“Compliance is often mediocre with deleterious consequences [1].”
Background
The expert consensus guideline series. Pharmacotherapy of depressive disorders in older patients.
Alexopoulos, G. S., Katz, I. R., Reynolds, C. F., Carpenter, D., & Docherty, J. P. (2001) · PubMed · Cited by 175 · see citing works
Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics
Kishimoto, T., Agarwal, V., Kishi, T., Leucht, S., Kane, J. M., & Correll, C. U. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.143 · Cited by 170 · cited 1× · see citing works
“However, a meta-analysis which considered all oral SGA as a single group demonstrated that they were associated with fewer relapses, less treatment failures and fewer hospitalizations in the long-term treatment of schizophrenia [40].”
Background
Clinical practice guidelines. Treatment of schizophrenia.
(2005) · PubMed · Cited by 156 · see citing works
Attitudes of Psychiatrists Toward Antipsychotic Depot Medication
Heres, S., Hamann, J., Kissling, W., & Leucht, S. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1216 · Cited by 152 · cited 2× · see citing works
“Several factors that deter psychiatrists from using depot forms have been identified, stemming from mistaken beliefs about good adherence, patient refusal, perceived coercion or a presumed risk of lower tolerance [13,15].”
Background
Clinical guideline recommendations for antipsychotic long-acting injections
Kane, J. M., & García-Ribera, C. (2009) · The British Journal of Psychiatry · doi:10.1192/bjp.195.52.s63 · Cited by 147 · see citing works
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Personality Disorders
Herpertz, S., Zanarini, M., Schulz, C., Siever, L., Lieb, K., & Möller, H. (2007) · World Journal of Biological Psychiatry · doi:10.1080/15622970701685224 · Cited by 143 · cited 1× · see citing works
“For personality disoreders, LAI FGA and LAI SGA are only recommended as a 2nd line treatment after usual pharmacological strategies [22].”
Background
Clinical practice recommendations for bipolar disorder
Malhi, G. S., Adams, D., Lampe, L. A., Paton, M. B., O’Connor, N., Newton, L., Walter, G., Taylor, A., Porter, R., Mulder, R., et al. (2009) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2009.01383.x · Cited by 125 · cited 1× · see citing works
“Indeed, the current EBG for biological treatment of schizophrenia and bipolar disorder [8-10,45-53] propose few recommendations concerning LAI antipsychotics.”
Background
Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases
Detke, H. C., McDonnell, D., Brunner, E., Zhao, F., Sorsaburu, S., Stefaniak, V. J., & Corya, S. A. (2010) · BMC Psychiatry · doi:10.1186/1471-244x-10-43 · Cited by 118 · see citing works
Antipsychotic treatment for schizophrenia in the maintenance phase: a systematic review of the guidelines and algorithms
Takeuchi, H., Suzuki, T., Uchida, H., Watanabe, K., & Mimura, M. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2011.11.021 · Cited by 115 · cited 2× · see citing works
“Most guidelines for the treatment of psychiatric disorders are evidence-based guidelines (EBG) [11,20].”
Background
Antipsychotic long-acting injections: Prescribing practice in the UK
Barnes, T. R. E., Shingleton‐Smith, A., & Paton, C. (2009) · The British Journal of Psychiatry · doi:10.1192/bjp.195.52.s37 · Cited by 114 · cited 2× · see citing works
“Nevertheless, depot formulations are still poorly used overall in routine practice, with prescription rates in different countries generally no more than 25% [12,13].”
Background
Why aren't depot antipsychotics prescribed more often and what can be done about it?
Patel, M. X., & David, A. S. (2005) · Advances in Psychiatric Treatment · doi:10.1192/apt.11.3.203 · Cited by 109 · cited 3× · see citing works
“Nevertheless, depot formulations are still poorly used overall in routine practice, with prescription rates in different countries generally no more than 25% [12,13].”
Background
The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary.
Alexopoulos, G. S., Jeste, D. V., Chung, H., Carpenter, D., ROSS, R. W., & Docherty, J. P. (2005) · PubMed · Cited by 99 · see citing works
Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection
Emsley, R. A., Oosthuizen, P., Koen, L., Niehaus, D. J. H., Medori, R., & Rabinowitz, J. (2008) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32830c2042 · Cited by 99 · cited 1× · see citing works
“Recent studies have underlined the fact that their use, as early as the first psychotic episode, offers many advantages in terms of efficacy, tolerance and improved adherence [31-33].”
Background
Effectiveness of risperidone long-acting injection in first-episode schizophrenia: In naturalistic setting
Kim, B., Lee, S., Choi, T.-K., Suh, S.-Y., Kim, Y. W., Lee, E., & Yook, K. H. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.03.012 · Cited by 95 · cited 1× · see citing works
“Recent studies have underlined the fact that their use, as early as the first psychotic episode, offers many advantages in terms of efficacy, tolerance and improved adherence [31-33].”
Background
Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS)
Grimaldi‐Bensouda, L., Rouillon, F., Astruc, B., Rossignol, M., Bénichou, J., Falissard, B., Limosin, F., Beaufils, B., Vaïva, G., Verdoux, H., et al. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.10.022 · Cited by 90 · cited 1× · see citing works
“of hospitalization compared to the use of other LAI FGA [43].”
Result
Patterns of neuroleptic drug prescription: a national cross‐sectional survey of a random sample of French psychiatrists
Fourrier, A., Gasquet, I., Allicar, M. P., Bouhassira, M., Lepine, J. P., & Bégaud, B. (2000) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2000.00108.x · Cited by 77 · cited 1× · see citing works
“5%) [14] and the United Kingdom (29%) [12] compared to other European countries.”
Background
Oral versus injectable antipsychotic treatment in early psychosis: Post hoc comparison of two studies
Emsley, R. A., Oosthuizen, P., Koen, L., Niehaus, D. J. H., Medori, R., & Rabinowitz, J. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.12.020 · Cited by 72 · cited 1× · see citing works
“Recent studies have underlined the fact that their use, as early as the first psychotic episode, offers many advantages in terms of efficacy, tolerance and improved adherence [31-33].”
Background
Second-generation antipsychotic long-acting injections: Systematic review
Fleischhacker, W. W. (2009) · The British Journal of Psychiatry · doi:10.1192/bjp.195.52.s29 · Cited by 68 · cited 2× · see citing works
“If their use in schizophrenia is common and supported by evidence [5-7,28], their use in bipolar disorder is less obvious.”
BackgroundResult
Risk of rehospitalization among bipolar disorder patients who are nonadherent to antipsychotic therapy after hospital discharge
Hassan, M., & Lage, M. J. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp080374 · Cited by 65 · cited 1× · see citing works
“Considering the risks associated with non-compliance in bipolar patients [38,39], the experts’ panel recommends LAI antipsychotics as a second-line treatment in bipolar disorder.”
Background
Establishing remission and good clinical functioning in schizophrenia: Predictors of best outcome with long-term risperidone long-acting injectable treatment
Lambert, M., Marinis, T. D., Pfeil, J., Naber, D., & Schreiner, A. (2009) · European Psychiatry · doi:10.1016/j.eurpsy.2009.09.001 · Cited by 62 · cited 1× · see citing works
“In recent years the interest of using LAI SGA in the early phase of schizophrenia has increased because the duration of untreated psychosis is associated with the prognosis of the illness [30].”
Background
Time to discontinuation of first- and second-generation antipsychotic medications in the treatment of schizophrenia
Kreyenbuhl, J. A., Slade, E. P., Medoff, D. R., Brown, C. H., Ehrenreich, B., Afful, J., & Dixon, L. B. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.04.028 · Cited by 60 · cited 1× · see citing works
“For example, the majority of patients with schizophrenia (84%) discontinue their index antipsychotic during the follow-up period [2] and in the long-term perspective, 40 to 50% seem to be noncompliant [3], with no real difference in terms of adherence between first-generation antipsychotics (FGA) and second-generation…”
Background
Poor adherence to treatment associated with a high recurrence in a bipolar disorder outpatient sample
Gutiérrez-Rojas, L., Jurado, D., Martínez-Ortega, J. M., & Manuel Gurpegui, A. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.05.021 · Cited by 46 · see citing works
Medication Treatment of Bipolar Disorder 2000: A Summary of the Expert Consensus Guidelines
Kahn, D. A., SACHS, G. S., PRINTZ, D. J., Carpenter, D. P., Docherty, J. P., & ROSS, R. W. (2000) · Journal of Psychiatric Practice · doi:10.1097/00131746-200007000-00004 · Cited by 42 · cited 1× · see citing works
“This method is very close to the Expert Consensus Guidelines methodology and has been applied to a variety of psychiatric disorders [4,21-27].”
Method
Psychiatrists’ awareness of adherence to antipsychotic medication in patients with schizophrenia: results from a survey conducted across Europe, the Middle East, and Africa
Olivares, J. M., Alptekın, K., Azorin, J., Cañas, Dubois, Emsley, R., Gorwood, P. A. P. M., Haddad, P. M., Naber, Papageorgiou, et al. (2013) · Patient Preference and Adherence · doi:10.2147/ppa.s37534 · Cited by 39 · cited 1× · see citing works
“This is consistent with the results of a survey conducted among psychiatrists from Europe, Middle-East and Africa, in which clinicians considered switching to or adding an LAI antipsychotic as the preferential pharmacological approach for addressing adherence problems [34].”
Result
Identifying the profile of optimal candidates for antipsychotic depot therapy
Heres, S., Hamann, J., Mendel, R., Wickelmaier, F., Pajonk, F., Leucht, S., & Kissling, W. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.09.025 · Cited by 36 · cited 2× · see citing works
“A cluster analysis of French and German studies, surveying psychiatrists about patient attributes that potentially influence their qualification for depot treatment, identified two clusters of patients [35,36].”
Background
Neurocognition as a Determinant of Employment Status in Schizophrenia
McGurk, S. R. (2000) · Journal of Psychiatric Practice · doi:10.1097/00131746-200007000-00003 · Cited by 35 · see citing works
Guidelines for the Use of Long-Acting Injectable Atypical Antipsychotics
Kane, J. M., Conley, R. R., Keith, S. J., Nasrallah, H. A., & Turner, M. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0121 · Cited by 33 · cited 2× · see citing works
“In addition to these EBG, there are some CBG focusing on the use and management of LAI formulations for the treatment of schizophrenia [4,27,54-57].”
BackgroundMethod
The expert consensus guideline series. Treatment of dementia and its behavioral disturbances.
(2005) · PubMed · Cited by 33 · see citing works
Dépistage et prise en charge du trouble bipolaire : Résultats
Llorca, P., Courtet, P., Martin, P., Abbar, M., Gay, C., Meynard, J.-A., Bayle, F., Hamon, M., Lançon, C., Thibaut, F., et al. (2010) · L Encéphale · doi:10.1016/s0013-7006(10)70037-3 · Cited by 33 · see citing works
Self-citation
Les antipsychotiques injectables à action prolongée: Avis d'experts de l'Association des médecins psychiatres du Québec
Stip, É., Abdel‐Baki, A., Bloom, D., Grignon, S., & Roy, M. (2011) · The Canadian Journal of Psychiatry · doi:10.1177/070674371105600608 · Cited by 33 · see citing works
International Consensus Group on Depression Prevention in Bipolar Disorder
Frye, M. A., Ha, K., Kanba, S., Kato, T., McElroy, S. L., Özerdem, A., Vázquez, G., & Vieta, E. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10123co1c · Cited by 31 · cited 1× · see citing works
“Indeed, the current EBG for biological treatment of schizophrenia and bipolar disorder [8-10,45-53] propose few recommendations concerning LAI antipsychotics.”
Background
Clinicians’ Attitudes Toward the Use of Long-Acting Injectable Antipsychotics
Samalin, L., Charpeaud, T., Blanc, O., Heres, S., & Llorca, P. (2013) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0b013e31829829c4 · Cited by 29 · cited 2× · see citing works
“A cluster analysis of French and German studies, surveying psychiatrists about patient attributes that potentially influence their qualification for depot treatment, identified two clusters of patients [35,36].”
BackgroundSelf-citation
How much more effective do depot antipsychotics have to be compared to oral antipsychotics before they are prescribed?
Hamann, J., Mendel, R., Heres, S., Leucht, S., & Kissling, W. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.01.001 · Cited by 29 · cited 1× · see citing works
“The negative attitudes of psychiatrists toward LAI antipsychotics mean they require a high level of evidence that depot formulation is clearly superior as a maintenance treatment to oral antipsychotics [58].”
Methodological differences between pharmacological treatment guidelines for bipolar disorder: what to do for the clinicians?
Samalin, L., Guillaume, S., Courtet, P., Abbar, M., Lancrenon, S., & Llorca, P. (2012) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2012.10.001 · Cited by 22 · cited 3× · see citing works
“Most guidelines for the treatment of psychiatric disorders are evidence-based guidelines (EBG) [11,20].”
BackgroundMethodSelf-citation
What is the evidence for the use of second-generation antipsychotic long-acting injectables as maintenance treatment in bipolar disorder?
Samalin, L., Nourry, A., Charpeaud, T., & Llorca, P. (2013) · Nordic Journal of Psychiatry · doi:10.3109/08039488.2013.801078 · Cited by 20 · cited 1× · see citing works
“Nevertheless, several placebo-controlled relapse prevention studies have shown the efficacy of risperidone microsphere as a monotherapy or as an adjunctive therapy to lithium or valproate in bipolar I patients [31].”
BackgroundSelf-citation
Dépistage et prise en charge du trouble bipolaire : Méthodologie
Llorca, P., Courtet, P., Martin, P., Abbar, M., Gay, C., Meynard, J.-A., Bayle, F., Hamon, M., Lançon, C., Thibaut, F., et al. (2010) · L Encéphale · doi:10.1016/s0013-7006(10)70036-1 · Cited by 16 · see citing works
Self-citation

Flagged first, then by citations

2 of the 66 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

Schizophrenia Core interventions in the treatment and management of schizophrenia in primary and secondary care (update) [ http://www.ncbi.nlm.nih.gov/pubmed/20704054] 20704054
NICE: National Institute for Health and Clinical Excellence The management of bipolar disorder in adults, children and adolescents, in primary and secondary care 2006 Alden Press UK. edn. London: The British Psychological Society and the Royal College of Psychiatrists 29718639

Sorted by citations

Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology
Goodwin, G., Haddad, P. M., Ferrier, I. N., Aronson, J., Barnes, T., Cipriani, A., Coghill, D., Fazel, S., Geddes, J. R., Grunze, H., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116636545 · Cited by 1,314 · see citing works
“When switching from an oral drug to an LAI form, it is good practice to start with the oral antipsychotic for the length of time required to establish the effective, best tolerated dose before switching to the LAI form (Llorca et al., 2013).”
The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal
Brissos, S., Veguilla, M. R., Taylor, D., & Balanzá-Martinez, V. (2014) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125314540297 · Cited by 297 · see citing works
Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder
Greene, M., Yan, T., Chang, E. Y., Hartry, A., Touya, M., & Broder, M. S. (2017) · Journal of Medical Economics · doi:10.1080/13696998.2017.1379412 · Cited by 200 · see citing works
Recent advances in long-acting drug delivery systems for anticancer drug
Pacheco, C., Baião, A., Ding, T., Cui, W., & Sarmento, B. F. C. C. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114724 · Cited by 193 · see citing works
Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics
Correll, C. U., Martin, A. L., Patel, C. A., Benson, C. J., Goulding, R., Sliwa, J. K., Joshi, K., Schiller, E., & Kim, E. (2022) · Schizophrenia · doi:10.1038/s41537-021-00192-x · Cited by 153 · see citing works
Long-acting injectable antipsychotics (LAIs) for maintenance treatment of bipolar and schizoaffective disorders: A systematic review
Pacchiarotti, I., Tiihonen, J., Kotzalidis, G. D., Verdolini, N., Murru, A., Goikolea, J. M., Valentí, M., Aedo, A., & Vieta, E. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2019.02.003 · Cited by 116 · see citing works
The role of shared decision-making in improving adherence to pharmacological treatments in patients with schizophrenia: A clinical review
Fiorillo, A., Barlati, S., Bellomo, A., Corrivetti, G., Nicolò, G., Sampogna, G., Stanga, V., Veltro, F., Maina, G., & Vita, A. (2020) · Annals of General Psychiatry · doi:10.1186/s12991-020-00293-4 · Cited by 110 · see citing works
“The current and future increasing availability of LAIs will enrich the choice for the clinicians who intend to use a long-acting formulation [67].”
Background
Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics
Pilon, D., Tandon, N., Lafeuille, M., Kamstra, R. L., Émond, B., Lefèbvre, P., & Joshi, K. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.08.008 · Cited by 98 · see citing works
“Second-generation long-acting injectable therapies (SGA-LAIs) are administered less frequently than oral APs (eg, biweekly, monthly, or once every 2 or 3 months compared with daily) and are recommended for patients with frequent relapses or adherence issues.(6,15) In addition to having a reduced dosing frequency, SGA-…”
Background
Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics
Heres, S., Lambert, M., & Vauth, R. (2014) · European Psychiatry · doi:10.1016/s0924-9338(14)70001-x · Cited by 84 · see citing works
The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics
Binder, M. D., Sermon, J., Geerts, P., Vansteelandt, K., Peuskens, J., & Detraux, J. (2015) · CNS Drugs · doi:10.1007/s40263-015-0269-4 · Cited by 78 · see citing works
Diverse definitions of the early course of schizophrenia—a targeted literature review
Newton, R., Rouleau, A., Nylander, A., Loze, J.-Y., Resemann, H. K., Steeves, S., & Crespo‐Facorro, B. (2018) · Schizophrenia · doi:10.1038/s41537-018-0063-7 · Cited by 78 · see citing works
“(2013) considered 'early course' to apply to patients who had been newly diagnosed with schizophrenia and who had had no previous antipsychotic treatment.(27) The Schizophrenia Patient Outcomes Research Team (2010) used the term “recent onset schizophrenia”, but no associated definition was specified.”
Background
Does formulation matter? A systematic review and meta-analysis of oral versus long-acting antipsychotic studies
Ostuzzi, G., Bighelli, I., So, R., Furukawa, T. A., & Barbui, C. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.11.010 · Cited by 78 · see citing works
“First, as LAIs allow a complete tracking of the drug consumption, theymay prevent thedevastating impact of the loss of even few doses of antipsychotic in early stages of the disease (Llorca et al., 2013; Patel, 2005; Stahl, 2014; Tiihonen et al., 2011).”
Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia
Kane, J., Mcevoy, J., Correll, C., & Llorca, P. (2021) · CNS Drugs · doi:10.1007/s40263-021-00861-6 · Cited by 74 · see citing works
Self-citation
Current therapeutic options for Huntington's disease: Good clinical practice versus evidence‐based approaches?
Killoran, A., & Biglan, K. (2014) · Movement Disorders · doi:10.1002/mds.26014 · Cited by 65 · see citing works
The modern perspective for long-acting injectables antipsychotics in the patient-centered care of schizophrenia
Pietrini, F., Albert, U., Ballerini, A., Calò, P., Maina, G., Pinna, F., Vaggi, M., Boggian, I., Fontana, M., Moro, C. G., et al. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s199048 · Cited by 61 · see citing works
“In the present study, the panel of experts recommended SGA LAIs as a first line treatment of schizophrenia in patients with cognitive impairment and poor functioning, since the lesser negative impact of SGA-LAIs on cognitive symptoms compared to FGA-LAIs allow for more productive involvement of the patient in rehabili…”
BackgroundInfluential
A comprehensive review of prioritised interventions to improve the health and wellbeing of persons with lived experience of homelessness
Moledina, A., Magwood, O., Agbata, E. N., Hung, J., Saad, A., Thavorn, K., Salvalaggio, G., Bloch, G. C., Ponka, D., Aubry, T., et al. (2021) · Campbell Systematic Reviews · doi:10.1002/cl2.1154 · Cited by 57 · see citing works
Long-Acting Injectable Antipsychotics in Schizophrenia: Literature Review and Practical Perspective, with a Focus on Aripiprazole Once-Monthly
Biagi, E., Capuzzi, E., Colmegna, F., Mascarini, A., Brambilla, G., Ornaghi, A., Santambrogio, J., & Clerici, M. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0507-x · Cited by 54 · see citing works
“Furthermore, the French Association for Biological Psychiatry and Neuropsychopharmacology guidelines for the use and management of antipsychotic depots in clinical practice recommend LAI antipsychotics be considered as first-line treatment in the majority of patients who require long-term therapy [32].”
Background
Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France
Druais, S., Doutriaux, A., Cognet, M., Godet, A., Lançon, C., Lévy, P., Samalin, L., & Guillon, P. (2016) · PharmacoEconomics · doi:10.1007/s40273-015-0348-x · Cited by 51 · see citing works
“Some consensusbased guidelines recommend the use of LAIs as a first-line treatment for most patients who require long-term antipsychotics [20, 21].”
BackgroundSelf-citation
Therapeutic Drug Monitoring of Long-Acting Injectable Antipsychotic Drugs.
Schoretsanitis, G., Baumann, P., Conca, A., Dietmaier, O., Giupponi, G., Gründer, G., Hahn, M., Hart, X., Havemann-Reinecke, U., Hefner, G., et al. (2020) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000830 · Cited by 28 · see citing works
Medication Adherence and Discontinuation of Aripiprazole Once-Monthly 400 mg (AOM 400) Versus Oral Antipsychotics in Patients with Schizophrenia or Bipolar I Disorder: A Real-World Study Using US Claims Data
Yan, T., Greene, M., Chang, E. Y., Hartry, A., Touya, M., & Broder, M. S. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0785-y · Cited by 50 · see citing works
A systematic review and secondary data analysis of the interactions between the serotonin transporter 5-HTTLPR polymorphism and environmental and psychological factors in eating disorders
Rozenblat, V., Ong, D., Fuller‐Tyszkiewicz, M., Akkermann, K., Collier, D. A., Engels, R. C. M. E., Fernández‐Aranda, F., Harro, J., Homberg, J. R., Karwautz, A. F. K., et al. (2016) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2016.09.023 · Cited by 46 · see citing works
Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics &ndash; expert consensus survey part 1
Sajatovic, M., Ross, R., Legacy, S. N., Correll, C. U., Kane, J. M., DiBiasi, F., Fitzgerald, H., & Byerly, M. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s167394 · Cited by 44 · see citing works
“16,18,36 Although disadvantages of LAIs include longer time to achieve steady state and less flexibility with dose adjustments, 1 LAIs may also simplify the treatment regimen and reduce patient medication-taking burden.”
BackgroundMethod
Real-world effectiveness of long-acting injectable antipsychotic treatments in a nationwide cohort of 12,373 patients with schizophrenia-spectrum disorders
Boyer, L., Falissard, B., Nuss, P., Collin, C., Duret, S., Rabbani, M., Chefdebien, I. D., Tonelli, I., Llorca, P., & Fond, G. B. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02175-z · Cited by 43 · see citing works
“As a consequence, many guidelines advocate LAIs for improving adherence to AP medication [15, 16].”
BackgroundSelf-citation
Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia
Pilon, D., Muser, E., Lefèbvre, P., Kamstra, R. L., Émond, B., & Joshi, K. (2017) · BMC Psychiatry · doi:10.1186/s12888-017-1358-3 · Cited by 43 · see citing works
“Consistent with this information, LAI should be considered earlier in the treatment of schizophrenia [34, 35], with some clinical guidelines recommending them in early schizophrenia [29] or as first-line treatment in schizophrenia patients (in the case of SG-LAI) [36].”
Method
A Systemic Review and Experts’ Consensus for Long-acting Injectable Antipsychotics in Bipolar Disorder
Chou, Y. H., Chu, P.-C., Wu, S.-W., Lee, J.-C., Lee, Y., Sun, I.-W., Chang, C., Huang, C.-L., Liu, I., Tsai, C.-F., et al. (2015) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2015.13.2.121 · Cited by 40 · see citing works
Long-acting injectable antipsychotics for the treatment of schizophrenia in Spain.
Arango, C., Baeza, I., Bernardo, M., Cañas, F., de Dios, C., Díaz-Marsá, M., García-Portilla, M., Gutiérrez-Rojas, L., Olivares, J. M., Rico-Villademoros, F., et al. (2019) · Revista de Psiquiatría y Salud Mental · doi:10.1016/j.rpsm.2018.03.006 · Cited by 25 · see citing works
Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder – expert consensus survey part 2
Sajatovic, M., ROSS, R. W., Legacy, S. N., Byerly, M., Kane, J. M., DiBiasi, F., Fitzgerald, H. M., & Correll, C. U. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s167485 · Cited by 38 · see citing works
“AFPBN guidelines recommend offering LAIs as first-line treatment to patients, but if the patient is going to be switched from an oral antipsychotic to an LAI, they recommend prescribing the oral antipsychotic to establish an effective dose before initiating the LAI.(18) The NICE schizophrenia guidelines recommend star…”
Influential
Long‐acting antipsychotic medication as first‐line treatment of first‐episode psychosis with comorbid substance use disorder
Abdel‐Baki, A., Thibault, D., Medrano, S., Stip, É., Ladouceur, M., Tahir, M. R., & Potvin, S. (2019) · Early Intervention in Psychiatry · doi:10.1111/eip.12826 · Cited by 39 · see citing works
“Although 48.9% of the sample eventually received LAI-AP, our data showed low levels of LAI-AP use as first treatment, despite expert recommendations (Llorca et al., 2013; NICE, 2014; Stip, AbdelBaki, Bloom, Grignon, & Roy, 2011).”
MethodResultInfluential
A further consideration on long-acting injectable versus oral antipsychotics in the treatment of schizophrenia: a narrative review and critical appraisal
Suzuki, T. (2016) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2016.1115479 · Cited by 40 · see citing works
Current and emerging long-acting antipsychotics for the treatment of schizophrenia
de Filippis, R., Fazio, P. D., Gaetano, R., Steardo, L., Cedro, C., Bruno, A., Zoccali, R., & Muscatello, M. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1910674 · Cited by 43 · see citing works
The treatment of schizophrenia: Can we raise the standard of care?
Catts, S. V., & O’Toole, B. I. (2016) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867416672725 · Cited by 35 · see citing works
“…LAIAs as best practice: there are highly respected CPG that recommend LAIAs as maintenance treatment from the first episode of schizophrenia (Llorca et al., 2013), contrary to the recommendations in the 2016 RANZCP CPG. Proposal for change: re-engineering the first hospital admission for…”
Drug Utilization of Japanese Patients Diagnosed with Schizophrenia: An Administrative Database Analysis
Cheung, S., Hamuro, Y., Mahlich, J., Nakahara, T., Sruamsiri, R., & Tsukazawa, S. (2017) · Clinical Drug Investigation · doi:10.1007/s40261-017-0517-0 · Cited by 33 · see citing works
“However, their use in the dementia population is disturbing because it is not evidence based and also not recommended by clinical experts [41].”
Background
A review on schizophrenia and relapse—a quest for user‐friendly psychopharmacotherapy
Suzuki, T., Uchida, H., Takeuchi, H., Tsuboi, T., Hirano, J., & Mimura, M. (2014) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2421 · Cited by 32 · see citing works
Chronic Hepatitis B Infection: New Approaches towards Cure
Ogunnaike, M., Das, S., Raut, S. S., Sultana, A., Nayan, M. U., Ganesan, M., Edagwa, B., Osna, N. A., & Poluektova, L. Y. (2023) · Biomolecules · doi:10.3390/biom13081208 · Cited by 33 · see citing works
“Recent advances in biomaterial and medicinal chemistry have led to innovations that have allowed for extended dosing schedules for various therapeutics, such as contraceptives [84], anti-psychotics [85,86], and HIV-1 therapies.”
Background
Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
Rocca, P., Montemagni, C., & Frieri, T. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s88632 · Cited by 31 · see citing works
“Lastly, the French Association for Biological Psychiatry and Neuropsychopharmacology recommends LAI as first-line treatment to patients with schizophrenia during maintenance treatment.(44)”
Comparative effectiveness of long-acting injectable risperidone vs. long-acting injectable first-generation antipsychotics in bipolar disorder
Wu, C., Hsieh, M. H., Tang, C., & Chang, C.-J. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.03.043 · Cited by 31 · see citing works
“Currently, LAI FGAs are not recommended for the maintenance treatment of bipolar disorder due to little evidence (Llorca et al., 2013).”
Background
Once-monthly paliperidone palmitate in recently diagnosed and chronic non-acute patients with schizophrenia
Hargarter, L., Bergmans, P., Chérubin, P., Keim, S., Conca, A., Serrano‐Blanco, A., Bitter, I., Bilanakis, N., & Schreiner, A. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1174692 · Cited by 31 · see citing works
Recommendations for the optimal care of patients with recent‐onset psychosis in the A sia‐ P acific region
Lo, T. L., Warden, M., He, Y., Si, T., Kalyanasundaram, S., Thirunavukarasu, M., Amir, N., Hatim, A., Bautista, T. C., Lee, C., et al. (2016) · Asia-Pacific Psychiatry · doi:10.1111/appy.12234 · Cited by 30 · see citing works
“, 2013) and as maintenance treatment following the initial episode (Llorca et al., 2013).”
Background
Management of Schizophrenia with Long-Acting Injectable Antipsychotic Medications: An Assessment of the Educational Needs of Clinicians
Citrome, L., Belcher, E. D., Stacy, S., Suett, M., Mychaskiw, M. A., & Salinas, G. D. (2022) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s326299 · Cited by 29 · see citing works
Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia
Brasso, C., Bellino, S., Bozzatello, P., Montemagni, C., & Rocca, P. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s150568 · Cited by 27 · see citing works
“However, they have potential advantages such as complete tracking of the drug consumption and full adherence in early stages of the disease.(45,46) In addition, LAIs do not need daily administration, which may be perceived by patients as a practical advantage, and minimize the risk of harmful drug use.”
Treatment discontinuation of long-acting injectables or oral atypical antipsychotics among Medicaid recipients with schizophrenia
Song, X., Khoury, A. C. E., Brouillette, M. A., Smith, D. M., & Joshi, K. (2019) · Journal of Medical Economics · doi:10.1080/13696998.2019.1615927 · Cited by 27 · see citing works
Reasons for initiating long-acting antipsychotics in psychiatric practice: findings from the STAR Network Depot Study
Barbui, C., Bertolini, F., Bartoli, F., Calandra, C., Callegari, C., Carrà, G., D’Agostino, A., Lucii, C., Martinotti, G., Mastromo, D., et al. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320978102 · Cited by 27 · see citing works
Practical considerations for managing breakthrough psychosis and symptomatic worsening in patients with schizophrenia on long-acting injectable antipsychotics
Correll, C. U., Sliwa, J. K., Najarian, D. M., & Saklad, S. R. (2019) · CNS Spectrums · doi:10.1017/s1092852918001098 · Cited by 27 · see citing works
Symptoms and functioning with aripiprazole once-monthly injection as maintenance treatment for bipolar I disorder
Calabrese, J. R., Sanchez, R., Jin, N., Amatniek, J. C., Cox, K., Johnson, B. R., Perry, P. P., Hertel, P., Such, P., McQuade, R. D., et al. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.10.035 · Cited by 26 · see citing works
Comparison of clinical outcomes in patients with schizophrenia following different long-acting injectable event-driven initiation strategies
Correll, C. U., Benson, C. J., Émond, B., Patel, C. A., Lafeuille, M., Lin, D., Morrison, L., Ghelerter, I., Lefèbvre, P., & Mavros, P. (2023) · Schizophrenia · doi:10.1038/s41537-023-00334-3 · Cited by 25 · see citing works
Clinical Decision-Making in the Treatment of Schizophrenia: Focus on Long-Acting Injectable Antipsychotics
Samalin, L., Garnier, M., Auclair, C., & Llorca, P.-M. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17111935 · Cited by 23 · see citing works
“One hypothesis could be that the recent development of specific French guidelines for the use and management of LAI antipsychotics in serious mental disorders [11,25], using a consensus-based methodology involving practitioners, facilitated their adherence and their use in clinical practice.”
Self-citation
Histoire des traitements antipsychotiques à action prolongée dans la schizophrénie
Crocq, M. A. (2015) · L Encéphale · doi:10.1016/j.encep.2014.12.002 · Cited by 23 · see citing works
Risperidone ISM as a New Option in the Clinical Management of Schizophrenia: A Narrative Review
Álamo, C. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02299-8 · Cited by 23 · see citing works
“The French Association of Biological Psychiatry and Neuropsychopharmacology clinical guideline recommends the use of second-generation LAIs as first-line treatment in the maintenance of patients after a first psychotic episode and in recent-onset schizophrenia [27].”
Background
Practical Guidance for the Use of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia
Riboldi, I., Cavaleri, D., Capogrosso, C. A., Crocamo, C., Bartoli, F., & Carrà, G. (2022) · Psychology Research and Behavior Management · doi:10.2147/prbm.s371991 · Cited by 22 · see citing works
“Indeed, available research offers little information which can support evidence-based choices.(19,29) In this review, we thus aimed at providing a practical guidance on the use of LAIs for the treatment of schizophrenia, summarizing the main characteristics of approved agents as well as the most recent evidence on rel…”
Method
Current and Emergent Treatments for Symptoms and Neurocognitive Impairment in Schizophrenia
Javitt, D. C. (2014) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-014-0010-9 · Cited by 23 · see citing works
Primary care physician's approach for mental health impact of COVID-19
Rohilla, J. K., Tak, P., Jhanwar, S., & Hasan, S. (2020) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_513_20 · Cited by 21 · see citing works
“However, they should avoid starting depot antipsychotic at primary care level, as it involves the risk of serious side effects like Neuroleptic malignant syndrome.[55]”
Background
Nurses' practices in the preparation and administration of intramuscular injections in mental health: A cross‐sectional study
Legrand, G., Guiguet‐Auclair, C., Viennet, H., Auméran, C., Reynaud, D., Badrikian, L., & Debost‐Legrand, A. (2019) · Journal of Clinical Nursing · doi:10.1111/jocn.14909 · Cited by 21 · see citing works
Impact of initiating long-acting injectable paliperidone palmitate on relapse and hospitalization in patients with bipolar I disorder: A mirror image retrospective study
Çalışkan, A. M., Çalışır, S., Çalışkan, S., Arslan, M. T., İnanlı, İ., & Eren, İ. (2020) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2020.102457 · Cited by 21 · see citing works
Aripiprazole Long-Acting Injection During First Episode Schizophrenia—An Exploratory Analysis
Giordano, G., Tomassini, L., Cuomo, I., Amici, E., Perrini, F., Callovini, G., Carannante, A., Kotzalidis, G. D., & Filippis, S. D. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00935 · Cited by 21 · see citing works
“In addition, the guidelines for the use and management of LAI antipsychotics in clinical practice by the French Assoc ia t ion for Bio log ica l Psychia t ry and Neuropsychopharmacology (AFPBN) suggest systematic offering of LAI antipsychotics as first line treatment to patients with schizophrenic who need maintenance…”
Background
Evaluating Monitoring Guidelines of Clozapine-Induced Adverse Effects: a Systematic Review
Smessaert, S., Detraux, J., Desplenter, S., & Binder, M. D. (2024) · CNS Drugs · doi:10.1007/s40263-023-01054-z · Cited by 20 · see citing works
Attitude and perceptions of patients towards long acting depot injections (LAIs)
Grover, S., Sahoo, S., Subodh, B. N., Malhotra, N., Dua, D., & Avasthi, A. (2019) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2019.07.052 · Cited by 19 · see citing works
Attitudes and Willingness to Accept Long-Acting Injections for Patients With Schizophrenia in Beijing: A Cross-Sectional Investigation Based on Samples From the Communities
Zhu, J., Chen, Y., Lu, W., Huang, Q., Li, B., Xu, Y., Xi, R., & Jin, L. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.770276 · Cited by 19 · see citing works
“Recent epidemiological studies have found that the prescription rates of LAI in clinical settings vary between 20 and 40% in European countries (23, 24, 36), but only 10.”
Background
Risk factors associated with readmissions of patients with severe mental disorders under treatment with antipsychotics
Portela, R., Wainberg, M. L., Castel, S., de Oliveira, H. N., & Ruas, C. M. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-03794-6 · Cited by 19 · see citing works
Population Pharmacokinetic Modeling and Simulation of TV‐46000: A Long‐Acting Injectable Formulation of Risperidone
Perlstein, I., Wagner, A. M., Goméni, R., Lamson, M. J., Harary, E., Spiegelstein, O., Kalmanczhelyi, A., Tiver, R., Loupe, P. S., Levi, M., et al. (2022) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1078 · Cited by 18 · see citing works
How can we improve the care of patients with schizophrenia in the real-world? A population-based cohort study of 456,003 patients
Fond, G. B., Falissard, B., Nuss, P., Collin, C., Duret, S., Rabbani, M., Chefdebien, I. D., Tonelli, I., Llorca, P., & Boyer, L. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02154-4 · Cited by 18 · see citing works
Self-citation
Medication adherence in patients with psychotic disorders: an observational survey involving patients before they switch to long-acting injectable risperidone
Misdrahi, D., Bayle, F., Tessier, A., & Bouju, S. (2015) · Patient Preference and Adherence · doi:10.2147/ppa.s89748 · Cited by 18 · see citing works
Changes in attitude towards LAI antipsychotic maintenance treatment: A two-year follow-up study
Pietrini, F., D’Anna, G., Tatini, L., Talamba, G. A., Andrisano, C., Calderani, E., Manetti, M., Prodi, P. R., Ricca, V., & Ballerini, A. (2018) · European Psychiatry · doi:10.1016/j.eurpsy.2018.06.002 · Cited by 18 · see citing works
“a) age between 18 and 65 years, b) hadbeenclinicallystableon astabilizedsingleoral AMTwitheither olanzapine, paliperidone or aripiprazole for more than 4 weeks, c) were about to be switched to the equivalent maintenance regimen with the LAI formulation of the same antipsychotic (olanzapine pamoate [39], paliperidone p…”
BackgroundMethodResultInfluential
Evidence-Based Expert Consensus Regarding Long-Acting Injectable Antipsychotics for Schizophrenia from the Taiwanese Society of Biological Psychiatry and Neuropsychopharmacology (TSBPN)
Yang, K.-C., Liao, Y.-T., Yang, Y.-K., Lin, S.-K., Liang, C.-S., & Bai, Y. (2021) · CNS Drugs · doi:10.1007/s40263-021-00838-5 · Cited by 16 · see citing works
Treatment Persistence Between Long-Acting Injectable Versus Orally Administered Aripiprazole Among Patients with Schizophrenia in a Real-World Clinical Setting in Japan
Iwata, N., Inagaki, A., Sano, H., Niidome, K., Kojima, Y., & Yamada, S. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01396-w · Cited by 18 · see citing works
Schizophrenia, the forgotten disorder: the scenario in Brazil
Matos, G., Guarniero, F. B., Hallak, J. E. C., & Bressan, R. A. (2015) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2015-1827 · Cited by 18 · see citing works
Adherence, persistence, and inpatient utilization among adult schizophrenia patients using once-monthly versus twice-monthly long-acting atypical antipsychotics
Pilon, D., Alcusky, M. J., Xiao, Y., Thompson‐Leduc, P., Lafeuille, M., Lefèbvre, P., & Benson, C. J. (2017) · Journal of Medical Economics · doi:10.1080/13696998.2017.1379413 · Cited by 16 · see citing works
A critical appraisal of paliperidone long-acting injection in the treatment of schizoaffective disorder
Chue, P. S., & Chue, J. (2016) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s81581 · Cited by 16 · see citing works
“LAIs in the management of SCA, with specific consideration of an SGA-LAI as the first-line strategy.(56,57) The development of an SGA-LAI for the treatment of SCA represents a logical step for an illness characterized by both psychotic and affective symptoms and is associated with poor adherence to oral therapies and…”
Method
Long-Acting Injectable Antipsychotics: Analysis of Prescription Patterns and Patient Characteristics in Mental Health from a Spanish Real-World Study
García-Carmona, J. A., Simal-Aguado, J., Campos-Navarro, M. P., Valdivia-Muñoz, F., & Galindo‐Tovar, A. (2020) · Clinical Drug Investigation · doi:10.1007/s40261-020-00913-7 · Cited by 16 · see citing works
Efficacy and acceptability of long-acting antipsychotics in acutely ill individuals with schizophrenia-spectrum disorders: A systematic review and network meta-analysis
Vita, G., Pollini, D., Canozzi, A., Papola, D., Gastaldon, C., Correll, C. U., Barbui, C., & Ostuzzi, G. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.116124 · Cited by 15 · see citing works
“As LAIs might have advantages over oral formulations in terms of medication adherence, timely use of LAIs has been recommended by evidence-based guidelines (Kane and Garcia-Ribera, 2009; Llorca et al., 2013).”
Background
Pharmacological Treatments of Negative Symptoms in Schizophrenia—An Update
Tsapakis, E.-M., Treiber, M., Mitkani, C. A., Drakaki, Z., Cholevas, A., Spanaki, C., & Fountoulakis, K. Ν. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13185637 · Cited by 15 · see citing works
“Moreover, the French guidelines on the use of long-acting antipsychotics state that SGA LAIs should be used as a second line of treatment for negative symptoms in schizophrenia [146].”
Background
Double stimuli-responsive polymer systems: How to use crosstalk between pH- and thermosensitivity for drug depots
Bogomolova, A., Kaberov, L. I., Sedláček, O., Filippov, S. K., Štěpánek, P., Král, V., Wang, X. Y., Liu, S., Ye, X., & Hrubý, M. (2016) · European Polymer Journal · doi:10.1016/j.eurpolymj.2016.09.010 · Cited by 15 · see citing works
Perceptions of Psychiatrists Toward the Use of Long-Acting Injectable Antipsychotics
Grover, S., Sahoo, S., & Mehra, A. (2019) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001109 · Cited by 15 · see citing works
“The indications of LAIs are currently not limited to only schizophrenia, but these have also been recommended for management of patients with schizoaffective disorder, delusional disorder, and bipolar disorder.(32) It has also been recommended in patients with firstepisode schizophrenia with proven benefits with regar…”
Background
The Disease Recovery Evaluation and Modification (DREaM) study: Effectiveness of paliperidone palmitate versus oral antipsychotics in patients with recent-onset schizophrenia or schizophreniform disorder
Alphs, L. D., Brown, B., Turkoz, I., Baker, P. C., Fu, D., & Nuechterlein, K. H. (2022) · Schizophrenia Research · doi:10.1016/j.schres.2022.02.019 · Cited by 15 · see citing works
“Clinical guidelines recommend treatment with LAIs in patients who prefer the injectable formulation and/or are at high risk of nonadherence and suggest consideration of LAIs in first-episode schizophrenia (American Psychiatric Association, 2020b; Kane and Correll, 2019; Llorca et al., 2013; National Council for Behavi…”
The effects of switching from oral to LAI antipsychotic treatment on subjective experience of schizophrenic and schizoaffective patients: Preliminary results
Pietrini, F., Spadafora, M., Talamba, G. A., Godini, L., Lelli, L., Arcabasso, S., Manetti, M., & Ballerini, A. (2014) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651501.2014.988268 · Cited by 15 · see citing works
“…are), the decision to change treatment strategy was made according to current clinical guidelines for the use and management of LAI antipsychotics (Llorca et al. 2013), suggesting that they should be considered and systematically proposed as a treatment option to any patient for whom maintenance…”
Method
Targets, attitudes, and goals of psychiatrists treating patients with schizophrenia: key outcome drivers, role of quality of life, and place of long-acting antipsychotics
Fagiolini, A. M., de Bartolomeis, A., Vaggi, M., & Vampini, C. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s96214 · Cited by 15 · see citing works
“Some guidelines, eg, the French Association for Biological Psychiatry and Neuropsychopharmacology guidelines, recommend that LAI antipsychotics should be considered as first-line therapy in any patient requiring long-term antipsychotic therapy.(47) While Italian experience with LAI antipsychotics in patients with firs…”
LAI versus oral: A case-control study on subjective experience of antipsychotic maintenance treatment
Pietrini, F., Spadafora, M., Tatini, L., Talamba, G. A., Andrisano, C., Boncompagni, G., Manetti, M., Ricca, V., & Ballerini, A. (2016) · European Psychiatry · doi:10.1016/j.eurpsy.2016.05.008 · Cited by 15 · see citing works
“The decision to change treatment strategy was made according to current clinical guidelines for the use and management of LAI antipsychotics [40], suggesting that they should be considered and systematically proposed as a treatment option to any patient for whom maintenance antipsychotic treatment is indicated.”
Method
Long-acting injectable antipsychotics for the treatment of schizophrenia in Spain
Arango, C., Baeza, I., Bernardo, M., Cañas, F., de Dios, C., Díaz-Marsá, M., García-Portilla, M., Gutiérrez-Rojas, L., Olivares, J., Rico-Villademoros, F., et al. (2019) · Revista de Psiquiatría y Salud Mental (English Edition) · doi:10.1016/j.rpsmen.2018.03.004 · Cited by 28 · see citing works
“In agreement with these recommendations from expert professionals in the Spanish setting, the French Association of Biological Psychiatry and Neuropsychopharmacology has published (2013) a guideline on the use and management of long-lasting injectable antipsychotics in severe mental disorder; the first-line recommenda…”
Result
A Long-Term Safety and Tolerability Study of TV-46000 for Subcutaneous Use in Patients with Schizophrenia: A Phase 3, Randomized, Double-Blinded Clinical Trial
Kane, J. M., Eshet, R., Harary, E., Tohami, O., Elgart, A., Knebel, H., Sharon, N. A., Suett, M., Franzenburg, K. R., Davis, G. L., et al. (2024) · CNS Drugs · doi:10.1007/s40263-024-01102-2 · Cited by 14 · see citing works
“Clinicians may also have misconceptions about patients’ perceptions of injection site pain and may focus on procedure rather than potential gains [33–36].”
Severe and persistent mental illness (SPMI) in pregnancy and breastfeeding: focus on second-generation long acting injectable antipsychotics
Orsolini, L., Sceusa, F., Pompili, S., Mauro, A., Salvi, V., & Volpe, U. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1928634 · Cited by 14 · see citing works
“the long-term treatment of such severe patients [17,18].”
Background
Guidelines for the use of second-generation long-acting antipsychotics
Jarema, M., Wichniak, A., Dudek, D., Samochowiec, J., Bieńkowski, P., & RYBAKOWSKI, J. K. (2015) · Psychiatria Polska · doi:10.12740/pp/39370 · Cited by 14 · see citing works
Paliperidone Palmitate Once-Monthly Treatment in Recent Onset and Chronic Illness Patients With Schizoaffective Disorder
Bossie, C. A., Turkoz, I., Alphs, L. D., Mahalchick, L., & Fu, D. (2016) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0000000000000646 · Cited by 14 · see citing works
“However, evidence suggests that their early initiation is associated with greater responsiveness, reduced risk for relapse, and improved long-term functioning (Heres et al., 2014; Kane et al., 2015; Llorca et al., 2013; Subotnik et al., 2015).”
Once-monthly injection of paliperidone palmitate in patients with recently diagnosed and chronic schizophrenia: a post-hoc comparison of efficacy and safety
Si, T., Zhuo, J., Turkoz, I., Mathews, M., Tan, W., & Feng, Y. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1401608 · Cited by 14 · see citing works
“within 5 years of diagnosis), in addition to their therapeutic use in chronic schizophrenia [30,48].”
BackgroundResult
Effectiveness of long-acting antipsychotics in clinical practice : 1. A retrospective, 18-month follow up and comparison between paliperidone palmitate, risperidone long-acting injection and zuclopenthixol decanoate
Cordiner, M., Shajahan, P., McAvoy, S., Bashir, M., & Taylor, M. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125315623168 · Cited by 16 · see citing works
Long-acting injectable (depot) antipsychotics and changing treatment philosophy: possible contribution to integrative care and personal recovery of schizophrenia.
Jakovljević, M. (2014) · PubMed · Cited by 13 · see citing works
Attitudes toward antipsychotic treatment among patients with bipolar disorders and their clinicians: a systematic review
Sajatovic, M., DiBiasi, F., & Legacy, S. N. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s139557 · Cited by 12 · see citing works
“40 A consensus rating scale was used in which respondents expressed levels of agreement or disagreement with survey questions, and these responses were then interpreted as recommended indications for first, second, or third-line treatment strategies for each diagnosis.”
Influential
An Attempt to Stem the Tide: Exploring the Effect of a 90-Day Transitional Care Intervention on Readmissions to an Acute Male Psychiatric Unit in South Africa
Botha, U. A., Coetzee, M., Koen, L., & Niehaus, D. J. H. (2017) · Archives of Psychiatric Nursing · doi:10.1016/j.apnu.2017.12.002 · Cited by 12 · see citing works
Switching long acting antipsychotic medications to aripiprazole long acting once-a-month: expert consensus by a panel of Italian and Spanish psychiatrists
Fagiolini, A. M., Alfonsi, E., Amodeo, G., Cenci, M., Lella, M. D., Farinella, F., Ferraiuolo, F., Fraguas, D., Loparco, N., Gutiérrez-Rojas, L., et al. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1155553 · Cited by 12 · see citing works
Comparison of Gluteal Muscle Intramuscular Injection Sites of Japanese Healthy Subjects: Considerations for Optimal Insertion of Injection Needle Length
Masuda, S., Yasuhara, Y., Tanioka, T., Atsuta, A., Motoki, K., Takase, K., & Locsin, R. C. (2016) · Open Journal of Psychiatry · doi:10.4236/ojpsych.2016.62025 · Cited by 12 · see citing works
“Also, in an evidence-based clinical approach, psychiatrists should be systematically offering to all patients that require long-term antipsychotic treatment, through shared decision-making, a LAI antipsychotic as a first-line treatment [2].”
Background
Factors related to improvement of symptoms, function, and caregiver burden in Chinese patients with schizophrenia after switching to paliperidone palmitate once-monthly from oral antipsychotics
Li, N., Feng, Y., Lu, H., Cai, S. L., Zhuo, J., Si, T., & Zhang, L. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s158353 · Cited by 12 · see citing works
Use of Long-Acting Injectable Antipsychotic in an Inpatient Unit of a Community Teaching Hospital
Olayinka, O. O., Oyelakin, A., Cherukupally, K., Virk, I., Ojimba, C., Khadka, S., Maksymenko, A., Fouron, P., Khandaker, T., Olupona, T., et al. (2019) · Psychiatry Journal · doi:10.1155/2019/8629030 · Cited by 12 · see citing works
“Similarly, while reviewing the extant literature to inform guidelines for LAI use in France, the authors found that LAI prescription rates are generally low across Europe; the United Kingdom reportedly had the highest LAI prescription rate of 29 percent [8].”
Background
Predictors of medication adherence in a large 1-year prospective cohort of individuals with schizophrenia: insights from the multicentric FACE-SZ dataset
Misdrahi, D., Dupuy, M., Dansou, Y., Boyer, L., Berna, F. S., Capdevielle, D., Chéreau, I., Coulon, N., d’Amato, T., Dubertret, C., et al. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02640-x · Cited by 11 · see citing works
“While the sample was composed of outpatients referred to the various expert centers for diagnosis or treatment issues, the 10 expert centers cover a large area of the French territory and as a result integrated a wide range of socioeconomic and cultural differences.”
BackgroundSelf-citation
The Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations, Outcomes (REACH-OUT) study: real-world clinical practice in schizophrenia
Joshi, K., Mao, L., Biondi, D. M., & Millet, R. A. (2018) · BMC Psychiatry · doi:10.1186/s12888-018-1594-1 · Cited by 11 · see citing works
Prescription patterns in psychiatric compulsory care: polypharmacy and high-dose antipsychotics
Kaikoushi, K., Karanikola, M. N. K., Middleton, N., Bella, E., & Chatzittofis, A. (2021) · BJPsych Open · doi:10.1192/bjo.2021.982 · Cited by 11 · see citing works
Long-term efficacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophrenia
Si, T., Zhuo, J., Feng, Y., Lu, H., Di, H., & Zhang, L. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s191803 · Cited by 11 · see citing works
PROTOCOL: A comprehensive review of prioritized interventions to improve the health and wellbeing of persons with lived experience of homelessness
Pottie, K. C., Mathew, C. M., Mendonca, O., Magwood, O., Saad, A., Abdalla, T., Stergiopoulos, V., Bloch, G. C., Brcic, V., Andermann, A. A. J., et al. (2019) · Campbell Systematic Reviews · doi:10.1002/cl2.1048 · Cited by 9 · see citing works
“Lastly, long‐acting Injectable antipsychotics are effective for managing numerous serious mental disorders, such as schizophrenia, delusional disorder, and bipolar disorder (Llorca et al., 2013).”
Long-acting antipsychotic treatments: focus on women with schizophrenia
Brissos, S., & Balanzá‐Martínez, V. (2024) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253241263715 · Cited by 10 · see citing works
“3,5 Treatment guidelines have been very conservative on the use of LAI-APs, 6,7 especially regarding their early implementation, 6 even though some already state that ‘patients should be offered the option of depot/long-acting injectable AP medication for maintenance treatment, given the evidence…”
Background
The Impact of Drug Delivery Systems on Pharmacokinetics and Drug-Drug Interactions in Neuropsychiatric Treatment
Nammas, M. (2025) · Cureus · doi:10.7759/cureus.85563 · Cited by 10 · see citing works
“Meta-analyses of LAI use in schizophrenia have shown significant improvements in medication adherence, symptom remission, and relapse prevention compared to oral anti-psychotics [53].”
Treatment Duration With Long-Acting Injectable Antipsychotics After In-hospital Initiation
Rittmannsberger, H., Rosenleitner, J., Malsiner‐Walli, G., Werl, R., Rittmannsberger, B., & Yazdi, K. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000672 · Cited by 10 · see citing works
“Some authors even argue that there is no evidence at all that use of LAI alone can improve patient adherence and that LAI should be given only to patients with a clear willingness to adhere.(18,19) Nevertheless, the statement that “poor insight and severe psychopathology in the absence of sufficient supervision favor…”
Evaluation of a comprehensive information and assistance program for patients with schizophrenia treated with long-acting injectable antipsychotics
Benson, C. J., Joshi, K., Lapane, K. L., & Fastenau, J. M. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1050365 · Cited by 10 · see citing works
Self- and caregiver-perceived disability, subjective well-being, quality of life and psychopathology improvement in long-acting antipsychotic treatments: a 2-year follow-up study
Pietrini, F., Tatini, L., Santarelli, G., Brugnolo, D., Squillace, M., Bozza, B., Ballerini, A., Ricca, V., & D’Anna, G. (2021) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2021.1912358 · Cited by 10 · see citing works
“…service between January 2016 and July 2017 who required a long-term antipsychotic treatment was offered to switch to LAI AMT, according to current clinical guidelines suggesting that LAIs should be systematically considered and proposed to any patient for whom AMT is indicated (Llorca et al. 2013).”
BackgroundMethod

1152 – Formalized Consensus Guidelines For Use And Management Of Antipsychotic Depots
Samalin, L., Guillaume, S., Abbar, M., Courtet, P., Lancrenon, S., & Llorca, P. (2013) · European Psychiatry · doi:10.1016/s0924-9338(13)76245-x
Self-citation
Clinical guideline recommendations for antipsychotic long-acting injections
Kane, J. M., & García-Ribera, C. (2009) · The British Journal of Psychiatry · doi:10.1192/bjp.195.52.s63 · Cited by 147 · see citing works
Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics &ndash; expert consensus survey part 1
Sajatovic, M., Ross, R., Legacy, S. N., Correll, C. U., Kane, J. M., DiBiasi, F., Fitzgerald, H., & Byerly, M. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s167394 · Cited by 44 · see citing works
Long-acting injectable antipsychotics: what, when, and how
Citrome, L. (2021) · CNS Spectrums · doi:10.1017/s1092852921000249 · Cited by 41 · see citing works
26.4 A U.S. EXPERT CONSENSUS SURVEY ON THE USE OF LONG-ACTING INJECTABLE ANTIPSYCHOTIC DRUGS IN PATIENTS WITH SCHIZOPHRENIA, SCHIZOAFFECTIVE DISORDER AND BIPOLAR DISORDER
Sajatovic, M. (2019) · Schizophrenia Bulletin · doi:10.1093/schbul/sbz022.109

Authors: Llorca, P. M., Abbar, M., Courtet, P., Guillaume, S., Lancrenon, S., & Samalin, L.
Affiliations: Centre Hospitalier Universitaire de Nîmes (FR)
Inserm (FR)
Centre Hospitalier Universitaire de Clermont-Ferrand (FR)
Corresponding author: Samalin, Ludovic
ORCID: Llorca, Pierre Michel
Abbar, Mocrane
Courtet, Philippe
Samalin, Ludovic
Venue: BMC Psychiatry
Publisher: Springer Science and Business Media LLC
Published: 2013-12
Volume: 13
Issue: 1
Pages: 340-340
ISSN: 1471-244X (ISSN-L)
DOI: 10.1186/1471-244x-13-340
PMC: PMC3898013
OpenAlex: W1982746840
Cited by: 188
References: 66
Citations by year: 2026: 12 · 2025: 12 · 2024: 14 · 2023: 14 · 2022: 24 · 2021: 16 · 2020: 10 · 2019: 18 · 2018: 11 · 2017: 17 · 2016: 20 · 2015: 12 · 2014: 8
FWCI: 9.48
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
www.springer.com/tdm (unspecified)
Locations: BMC Psychiatry (publishedVersion, cc-by)
Europe PMC (PubMed Central) (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
HAL (submittedVersion, other-oa)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Social Sciences › Psychology › Clinical Psychology › Psychiatric care and mental health services
Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
Keywords: long-acting injectable antipsychotics, severe mental illness, schizophrenia, bipolar disorder, schizoaffective disorder, delusional disorder, long-term antipsychotic treatment, relapse prevention, medication adherence, medication management, atypical antipsychotics, typical antipsychotics, shared decision-making
MeSH terms: Adult, Aged, Attitude of Health Personnel, Mental Disorders, Delayed-Action Preparations, Female, Humans, Injections, Intramuscular, Male, Middle Aged, Practice Patterns, Physicians', Schizophrenia, Severity of Illness Index, Antipsychotic Agents, United States, Practice Guidelines as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks